Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of its two lead products, Tempol and QuitPak®, through Phase II clinical trials while leveraging $1.2 million in current financing from its strategic development partner, Cardinal Health, and $10.8 million in NIH grants. The Company is led by an experienced management team and Board of Directors, including Douglas Cary (President), a former Abbott Laboratories executive; Carl Schwan (CFO), a former CFO for two successful initial public offerings that raised $80 million; Dr. Lester Crawford (Director), Former Commissioner of the U.S. Food and Drug Administration (FDA); and Stephen Norris (Director), Co-founder and Past President of the Carlyle Group and Chairman of SN Partners, a private equity investment firm.